Literature DB >> 9731983

H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications.

D Y Graham1, Y Yamaoka.   

Abstract

BACKGROUND: Helicobacter pylori infection is accepted to be associated with two mutually exclusive diseases: duodenal ulcer and gastric cancer. Attention has recently focused on possible relationships between H. pylori and gastroesophageal reflux disease and its complications such as adenocarcinoma of the gastric cardia. The aim of this study was to provide a framework for explaining the seemingly paradoxical associations between H. pylori and various gastrointestinal diseases.
METHODS: Available data regarding H. pylori infection, cagA, acid secretion, corpus gastritis, and gastroesophageal reflux disease (GERD) and its complications are reviewed, and testable hypotheses are presented.
RESULTS: Linking the type of H. pylori (cagA-positive vs. cagA-negative), the pattern and intensity of inflammation, and acid secretion explains the apparent paradoxes in the associations between H. pylori and gastric cancer, duodenal ulcer, and GERD. Although H. pylori is inhibited by bile, a duodenal acid load sufficient to lower the average pH to precipitate bile acids overcomes that inhibition. H. pylori that contain a functional cag pathogenicity island produce a vigorous inflammatory response. The severity of mucosal inflammation predicts likelihood of different outcomes (e.g., in the bulb with likelihood of developing duodenal ulcer, and in the corpus with the degree of reduction in acid secretion and the rate of development of multifocal atrophic gastritis). Development of H. pylori corpus gastritis is promoted by profound inhibition of acid secretion (e.g., childhood infections or a high level of antisecretory therapy). The CagA protein, or the cagA gene, is a marker for enhanced inflammation, but CagA is not directly involved in the pathogenesis of gastric cancer or duodenal ulcer disease, nor is it a reliable indicator of the presence of a functional cag pathogenicity island.
CONCLUSION: The relationship between the type of H. pylori infection, presence or absence of a functional cag pathogenicity island, corpus inflammation, and acid secretion explains the duodenal ulcer/gastric cancer paradox and the relationship between H. pylori infection and the complications of GERD. The predicted rank order for the presence of GERD and its complications (peptic stricture, Barrett's esophagus, and adenocarcinoma of the gastric cardia) is highest in the population without H. pylori infection, less in those with H. pylori infection, and least in those infected with cagA-positive H. pylori. Controversy and confusing epidemiological observations will continue unless future studies provide data on the gastric corpus histology (or acid secretion) as well as regarding the presence or absence of a functional and intact cag pathogenicity island of the infecting organism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9731983     DOI: 10.1046/j.1523-5378.1998.08031.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  41 in total

1.  The phenotype of gastric mucosa coexisting with Barrett's oesophagus.

Authors:  M Rugge; V Russo; G Busatto; R M Genta; F Di Mario; F Farinati; D Y Graham
Journal:  J Clin Pathol       Date:  2001-06       Impact factor: 3.411

Review 2.  New approaches to Helicobacter pylori infection in children.

Authors:  B D Gold
Journal:  Curr Gastroenterol Rep       Date:  2001-06

3.  Helicobacter pylori is not and never was "protective" against anything, including GERD.

Authors:  David Y Graham
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

4.  CagA in Barrett's oesophagus in Colombia, a country with a high prevalence of gastric cancer.

Authors:  M Kudo; O Gutierrez; H M T El-Zimaity; H Cardona; Z Z Nurgalieva; J Wu; D Y Graham
Journal:  J Clin Pathol       Date:  2005-03       Impact factor: 3.411

Review 5.  Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?

Authors:  J Lagergren
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

6.  Monitoring the disulfide bond formation of a cysteine-rich repeat protein from Helicobacter pylori in the periplasm of Escherichia coli.

Authors:  Venkataramani Sathya Devi; Peer R E Mittl
Journal:  Curr Microbiol       Date:  2010-11-04       Impact factor: 2.188

Review 7.  Contemplating the future without Helicobacter pylori and the dire consequences hypothesis.

Authors:  David Y Graham; Yoshio Yamaoka; Hoda M Malaty
Journal:  Helicobacter       Date:  2007-11       Impact factor: 5.753

8.  Characterization of a novel Helicobacter pylori East Asian-type CagA ELISA for detecting patients infected with various cagA genotypes.

Authors:  Dalla Doohan; Muhammad Miftahussurur; Yuichi Matsuo; Yasutoshi Kido; Junko Akada; Takeshi Matsuhisa; Than Than Yee; Kyaw Htet; Hafeza Aftab; Ratha-Korn Vilaichone; Varocha Mahachai; Thawee Ratanachu-Ek; Lotay Tshering; Langgeng Agung Waskito; Kartika Afrida Fauzia; Tomohisa Uchida; Ari Fahrial Syam; Yudith Annisa Ayu Rezkitha; Yoshio Yamaoka
Journal:  Med Microbiol Immunol       Date:  2019-09-23       Impact factor: 3.402

9.  Genetic association of interleukin-1 haplotypes with gastritis and precancerous lesions in North Indians.

Authors:  B R Achyut; N Moorchung; B Mittal
Journal:  Clin Exp Med       Date:  2008-04-03       Impact factor: 3.984

10.  Does seropositivity for Helicobacter pylori antibodies increase outpatient costs for gastric and duodenal ulcer or inflammation?

Authors:  Akira Babazono; Motonobu Miyazaki; Hiroshi Une; Eiji Yamamoto; Toshihide Tsuda; Yoshio Mino; Alan L Hillman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.